Until recently, we were focused on the research and development of novel therapeutics for neurodegenerative diseases, such as Niemann Pick disease type C (NPC).

In May 2022, substantially all our assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc.